

Targeting Glycolate Oxidase for the Treatment of Primary Hyperoxaluria Type 1: Development and Clinical Characterization of Lumasiran, an RNAi Therapeutic

Hadas Shasha-Lavsky, MD¹; Arnaud Devresse, MD, PhD²; Fitsum Guebre-Egziabher, MD, PhD³; Wesley Hayes, MBBChir⁴; Julien Hogan, MD, PhD⁵; Sally-Anne Hulton, MD⁶; Daniella Magen, MD⁷; Chebl Mourani, MD⁸; J. Scott Overcash, MD⁹; Jeffrey M. Saland, MD¹⁰; Rola Saqan, MD¹¹; David J. Sas, DO, MPH¹²; Eva Simkova, MD¹³; Richard Singer, MChB¹⁴; Nune Makarova, MD, MPH¹⁵; Cristin Kaspar, MD¹⁶; John M. Gansner, MD, PhD¹⁵; Anne-Laure Sellier-Leclerc, MD¹⁶

¹Pediatric Nephrology Unit, Galilee Medical Center, Azrieli Faculty of Medicine, Bar-Ilan University, Nahariya, Israel; ²Division of Nephrology, Cliniques Universitaires Saint-Luc, Brussels, Belgium; ³Nephrology and Renal Function Unit, Edouard Herriot Hospital, Hospices Civils de Lyon, INSERM 1060, Lyon, France; ⁴Department of Paediatric Nephrology, Great Ormond Street Hospital, London, UK; ⁵Pediatric Nephrology Department, Hôpital Robert-Debré, APHP, Paris, France; ⁶Birmingham Women's and Children's Hospital, Birmingham, UK; ⁷Pediatric Nephrology Institute, Haifa, Israel; ⁸Pediatrics, Hôtel-Dieu de France Hospital (HDF), Beirut, Lebanon; ⁹Velocity Clinical Research, San Diego, CA, USA; ¹⁰Icahn School of Medicine at Mount Sinai, New York, NY, USA; ¹¹Pharmaceutical Research Center - Jordan University of Science and Technology, Irbid, Jordan; ¹²Division of Pediatric Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA; ¹³Al Jalila Children's Hospital, Dubai, United Arab Emirates; ¹⁴Canberra Health Services, Garran, ACT, Australia; ¹⁵Alnylam Pharmaceuticals, Cambridge, MA, USA; ¹⁶Hospices Civils de Lyon, Bron, France


Conclusions

- Lumasiran is the first approved treatment for PH1¹
- Lumasiran has been evaluated in clinical trials in 98 patients with PH1, with follow-up of up to 5 years
- Clinical trial data support the efficacy and safety of lumasiran in patients of all ages and varying levels of disease severity²
- With long-term lumasiran treatment, urine and plasma oxalate levels were reduced, kidney stone event rates and medullary nephrocalcinosis were generally stable or improved, and kidney function remained stable
- Lumasiran demonstrated an acceptable safety profile, with injection site reactions being the most commonly reported lumasiran-related AE^{3,4}

Lumasiran for the Treatment of PH1

- PH1, an autosomal recessive disease caused by deficient activity of the hepatic enzyme AGT, is associated with oxalate overproduction, progressive kidney damage, and eventual systemic oxalosis¹
- Lumasiran is a liver-directed siRNA that reduces oxalate levels by targeting mRNA encoding GO (Figure 1)
- The approval of lumasiran for the treatment of PH1^{3,4} in 2020 introduced the first disease-modifying option in the management of PH1²

Figure 1. Mechanism of Action of GO Inhibition for the Treatment of PH1^{5,6}



GO is a Favorable Target for Therapeutic Intervention

- GO has a number of characteristics that make it an attractive target for therapeutic intervention in PH1^{7,8} including:
 - Targeting GO specifically addresses the defect in PH1, as GO lies upstream of the molecular defect in PH1⁵
 - The physiological role of GO is thought to be restricted to metabolism of glycolate to glyoxylate, with no role in the Cori cycle, the Krebs cycle, or glucose availability⁹
 - GO has a highly restricted tissue distribution, being specifically expressed in the liver¹⁰
 - Mouse knockout models with complete inhibition of GO exhibit a normal phenotype, with only asymptomatic elevation of urine glycolate^{5,11}
 - A rare human null mutation with lifelong GO knockout exhibited no clinical phenotype¹²

Lumasiran Clinical Development Program

- The lumasiran clinical development program is robust, comprising trials that enrolled a total of 98 patients with a wide range of ages and varying levels of PH1 severity, including patients undergoing intensive hemodialysis (Table)
- A large, prospective, observational study (BONAPH1DE; NCT04982393) is being conducted to examine the long-term, real-world safety and effectiveness of lumasiran in patients with PH1
 - Patients diagnosed with PH1 are managed and treated per standard of care
 - The study is currently recruiting; estimated enrollment is 200 patients

Table. Clinical Trials of Lumasiran in PH1

| | Phase 1/2 ¹³ | Phase 2 Open-label Extension ¹⁴ | ILLUMINATE-A ¹⁵ | ILLUMINATE-B ¹⁶ | ILLUMINATE-C ¹⁷ |
|-------------------------------|---|--|--|---|--|
| ClinicalTrials.gov identifier | NCT02706886 | NCT03350451 | NCT03681184 | NCT03905694 | NCT04152200 |
| Phase | 1/2 | 2 | 3 | 3 | 3 |
| Design | Single-blind, placebo-controlled, single dose (Part A, healthy adults) and multiple ascending dose (Part B) study | Open-label extension for patients from Part B of the Phase 1/2 trial | Randomized, double-blind, placebo-controlled study with extension period | Single-arm, open-label study with extension period | Single-arm, open-label study with extension period |
| Participants (N) | 20 in Part B | 20 | 39 | 18 | 21 |
| Inclusion criteria | Part B: • PH1 • 6–64 years of age • 24-hour UOx excretion >0.7 mmol/24h/1.73m ² • eGFR >45 mL/min/1.73m ² | • Completed Phase 1/2 study (Part B) • In the opinion of the investigator, tolerated the study drug | • PH1 • ≥6 years of age • 24-hour UOx excretion >0.7 mmol/24h/1.73m ² • eGFR ≥30 mL/min/1.73m ² | • PH1 • <6 years of age • UOx:Cr greater than ULN for age • eGFR >45 mL/min/1.73m ² if ≥12 months of age or elevated serum creatinine if <12 months of age • Not on hemodialysis (Cohort A) or on stable hemodialysis regimen (Cohort B) | • PH1 • All ages eligible • POx ≥20 μmol/L • eGFR ≤45 mL/min/1.73m ² if ≥12 months of age or elevated serum creatinine if <12 months of age • Not on hemodialysis (Cohort A) or on stable hemodialysis regimen (Cohort B) |
| Status | Completed | Completed | Active, not recruiting; M36 data presented ¹⁸ | Active, not recruiting; M30 data presented ¹⁹ | Active, not recruiting; M12 data presented ²⁰ |
| Total study duration | 6 months | Up to 54 months | Up to 60 months | Up to 60 months | Up to 60 months |

Urinary Oxalate

Figure 2. Mean (SEM) 24-Hour UOx in ILLUMINATE-A






Figure 3. Mean (SEM) Spot UOx:Cr in ILLUMINATE-B



eGFR


- In the Phase 2 OLE study, mean eGFR values remained stable through Month 54

Figure 4. Mean (SEM) eGFR in ILLUMINATE-A, ILLUMINATE-B, and ILLUMINATE-C



Kidney Stone Events

Figure 5. Kidney Stone Event Rates




Nephrocalcinosis

- In both ILLUMINATE-A and ILLUMINATE-B, medullary nephrocalcinosis generally improved or remained stable with lumasiran treatment
 - ILLUMINATE-A: At Month 36, in the lumasiran/lumasiran group, 39% of patients had improvement, 50% were stable, and 11% had worsening (after 36 months of lumasiran). In the placebo/lumasiran group, 54% of patients improved, 36% were stable, and 9% had worsening (after 30 months of lumasiran). Overall, 43% of patients with medullary nephrocalcinosis at baseline had complete resolution
 - ILLUMINATE-B: At Month 24, nephrocalcinosis grade improved in 67% of patients, remained stable in 28%, and was indeterminate in 6%

Plasma Oxalate

Figure 6. Mean (SEM) POx Values in ILLUMINATE-C Over 12 Months



Safety

- ILLUMINATE-A: The most common AEs (≥15% of patients in the all-lumasiran-treated set during lumasiran treatment) were injection site reactions (49%), abdominal pain (21%), headache (18%), and COVID-19 (15%); 4 patients (10%) had serious AEs, none of which were considered related to the study drug
- ILLUMINATE-B: Lumasiran-related AEs were reported by 28% of patients, most commonly mild, transient injection site reactions (17%); there were no clinically relevant changes in laboratory measures, vital signs, or electrocardiograms related to lumasiran
- ILLUMINATE-C: At 12 months, the most common lumasiran-related AEs were mild, transient injection site reactions (24%); there were no serious or severe AEs related to lumasiran

Abbreviations: AE, adverse event; AGT, alanine-glyoxylate aminotransferase; BL, baseline; BSA, body surface area; CI, confidence interval; eGFR, estimated glomerular filtration rate; GI, gastrointestinal; GO, glyoxylate oxidase; GR, glyoxylate reductase; LDH, lactate dehydrogenase; M, month; NC, nephrocalcinosis; OLE, open-label extension; PH, primary hyperoxaluria; POx, plasma oxalate; PY, person-year; SEM, standard error of the mean; siRNA, small interfering ribonucleic acid; ULN, upper limit of normal; UOx, urinary oxalate; UOx:Cr, urinary oxalate:creatinine ratio.
 Disclosures: HS-L: principal investigator for Alnylam Pharmaceuticals; travel and accommodation expenses from Alnylam Pharmaceuticals to attend international investigators' meetings. AD: Principal investigator for Alnylam Pharmaceuticals; received consultancy fees from Alnylam Pharmaceuticals. FG-E: Principal investigator for Alnylam Pharmaceuticals. WH: travel and accommodation expenses from Alnylam Pharmaceuticals to attend an international investigators' meeting. JH: consultancy fees from Alnylam Pharmaceuticals. SAH: travel expenses to participate in clinical research meetings, consultancy fee from Advisory Board, and consultancy fees paid to Birmingham Children's Hospital Renal Research Fund from Alnylam Pharmaceuticals, and other from Dicerna Pharmaceuticals and Chiesi Pharmaceuticals. DM: research funding, consultancy fees, and non-financial support from Alnylam Pharmaceuticals. JMS: grants, personal fees, and non-financial support from Alnylam Pharmaceuticals. CM: Nothing to disclose. JSO: institutional research funding from Alnylam Pharmaceuticals. JMS: grants, personal fees, and non-financial support from Alnylam Pharmaceuticals. RS: Primary investigator for Alnylam Pharmaceuticals; secondary investigator for Novartis, and serves on the institutional review board. DJS: grants and other from Alnylam Pharmaceuticals and personal fees from Advicene. ES: principal investigator for Alnylam Pharmaceuticals; travel and accommodation expenses from Alnylam Pharmaceuticals to attend international investigators' meeting. MM & CK: employment by Alnylam Pharmaceuticals. JMS: employee of and shareholder in Alnylam Pharmaceuticals. ALS-L: consultancy fees from Alnylam Pharmaceuticals and Dicerna Pharmaceuticals, and principal investigator for research funded by OxThera.
 Acknowledgments: Thank you to the patients, their families, investigators, study staff, and collaborators for their participation in the lumasiran clinical studies. Medical writing and editorial assistance was provided by Peloton Advantage, LLC, an OPEN Health company, in accordance with Good Publication Practice (GPP 2022) guidelines and funded by Alnylam Pharmaceuticals.
 Funding: Alnylam Pharmaceuticals.
 References: 1. Hogan B, Martin-Higueras C. Drugs 2022;62:1077-1094. 2. Hulton S-A. Expert Opin Orphan Drugs 2021;9:189-198. 3. Oxluma [package insert]. Cambridge, MA: Alnylam Pharmaceuticals; 2022. 4. Oxluma [package insert]. Cambridge, MA: Alnylam Pharmaceuticals; 2022. 5. Liebow A, et al. J Am Soc Nephrol 2017;28:494-503. 6. Cochat P. Kidney Int 1999;55:2533-2547. 7. Forbes TA, et al. Br J Pharmacol 2022;88:2526-2538. 8. HAO1 hydroxyacyl oxidase 1. 2023. https://www.ncbi.nlm.nih.gov/ncbi/pov/pub/54363. Accessed: May 15, 2023. 9. Fritschberg Y, et al. J Med Genet 2014;51:526-529. 10. Jones JM, et al. J Biol Chem 2000;275:12590-12597. 11. Martin-Higueras C, et al. Mol Ther 2016;24:1719-1725. 12. McGregor TL, et al. Mol Ther 2016;24:1719-1725. 13. Frishberg Y, et al. Clin J Am Soc Nephrol 2021;16:1025-1036. 14. Magen D, et al. Kidney Int Rep 2022;7(2):S195-S198. 15. Garraffo S, et al. N Engl J Med 2021;384:1216-1226. 16. Sas DJ, et al. Genet Med 2022;24:654-662. 17. Michael M, et al. Am J Kidney Dis 2023;81:145-155. 18. Saland J, et al. Am J Kidney Dis 2023;81(4 suppl 1):S56-S57 [abstract 194]. 19. Michael M, et al. Efficacy and safety of Lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE trial [abstract]. 20. Frishberg Y, et al. J Am Soc Nephrol 2022;33:416 [abstract FR-P0335].